SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PolyMedix
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tnsaf4/21/2012 12:14:53 PM
   of 77
 
PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic

Conference Call and Webcast Scheduled for Monday, April 23rd at 9:00 AM

RADNOR, Pa., April 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB: PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, has scheduled a conference call and webcast for Monday, April 23rd at 9:00 AM Eastern Time. At that time, management will review the full results from the Phase 2 clinical trial with PMX-30063 defensin-mimetic antibiotic for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph aureus.

Participants may access this audio webcast through a live broadcast on the Company's website at www.polymedix.com or investors.polymedix.com. Participants should log onto the audio webcast at least 15 minutes prior to the call. The Internet presentation will be available for up to 90 days after the call at the Company's website.

The call in number is 877-771-7024. The international call in number is 678-905-9379. A replay of the conference call will be available two hours after the call's completion and remain available for seven days. The replay number to hear the conference call is 800-585-8367 or 404-537-3406. The passcode is 71350471.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News